TRUQAP 160 mg film-coated tablets, TRUQAP 200 mg film-coated tablets
D3612L00005
Phase 3 small_molecule active
Quick answer
TRUQAP 160 mg film-coated tablets, TRUQAP 200 mg film-coated tablets for HR+ / HER2- advanced breast cancer is a Phase 3 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- HR+ / HER2- advanced breast cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active